Phase II Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas
The purpose of this phase II trial is to evaluate the safety and efficacy of immunotherapy combinations in patients with pancreatic adenocarcinoma.
Study ID: J1568
Trial Phase: Phase II
Trial Sponsor: National Cancer Institute (NCI), Bristol-Myers Squibb, Sidney Kimmel Comprehensive Cancer Center
Therapies Used in This Trial: GVAX, Cyclophosphamide, Nivolumab, Urelumab, HuMax-IL8